-

Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in March:

  • Cowen and Company 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 8:00 a.m. ET at The Boston Marriott Copley Place in Boston.
  • Barclays Global Healthcare Conference on Thursday, March 12, 2020 at 10:45 a.m. ET at the Loews Miami Beach Hotel in Miami.

A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of refractory gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated certain GI diseases.

Ironwood was founded in 1998 and is headquartered in Boston, Mass. For more information, please visit our website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

Contacts

Investor and Media Relations
Meredith Kaya, 617-374-5082
Vice President, Strategy, Investor Relations and Corporate Communications
mkaya@ironwoodpharma.com

Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Release Versions

Contacts

Investor and Media Relations
Meredith Kaya, 617-374-5082
Vice President, Strategy, Investor Relations and Corporate Communications
mkaya@ironwoodpharma.com

Social Media Profiles
More News From Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website following the confe...

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be a...

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. “LINZESS continued to deliver robust prescription demand growth in the third quarter,” said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. “LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professiona...
Back to Newsroom